Roswell Park researchers are developing new approaches for treating CLL, including:
- Combining targeted agents such as BTK and BCL2 inhibitors with monoclonal antibodies targeting CD20. It’s hoped that this combination will have fewer side effects than chemotherapy.
- Creating new drugs for patients whose bodies may no longer respond to BTK or BCL2 inhibitors.
Roswell Park also offers eligible patients the chance to enroll in clinical trials of new and promising treatments.